Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07489287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Jan 15, 2028 → Aug 18, 2028
See other at-risk trials from Roswell Park Cancer Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jan 15, 2028 to Aug 18, 2028 Show 4 more changesShow less
    • Study completion pushed from Jan 15, 2030 to Aug 18, 2030
    • Start date changed from estimate of Jul 15, 2026 to Aug 18, 2026
    • Eligibility criteria expanded, about 79 words
    • Study description expanded, about 2 words
  2. Start date: Jun 15, 2026 to Jul 15, 2026v5
  3. Recruitment opened
    • Study sites: 0 to 1
    v4
  4. Eligibility criteria revisedv3
  5. Study title shortened, about 17 wordsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.
Trial Details
NCT Number NCT07489287
Lead Sponsor Roswell Park Cancer Institute
Collaborators: Generate Biomedicines
Conditions
(from sponsor)		 Platinum-resistant Ovarian Cancer
Related terms Ovarian Neoplasms
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov